Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Privacy Policy
  • Contact US

Insight, China's Pharmaceutical Industry Fineline Info & Tech is a comprehensive global pharmaceutical database that spans the entire product lifecycle. Its mission is to equip professionals and executives across all sectors of the life sciences industry with a standardized data language, offering a holistic view of the Chinese pharmaceutical competitive landscape. Flcube.com furnishes critical data essential for informed decision-making, drawing on global industry news, policy insights, competitive intelligence, and advanced analytical tools.

Company Deals PIC

Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent

Fineline Cube Sep 8, 2026
Company Deals PIC

Liaocheng University and Shanghai Maiboxing Biotechnology Sign RMB 19 Million Pact to Co‑Develop LCUGZ1007 – Next‑Generation E‑PDC Probody Drug Conjugate

Fineline Cube Sep 8, 2026
Company Deals PIC

China Biotech’s Panboron BNCT Hospital Signs Strategic Pact with OncoCare Cancer Centre HK – Launching Cross‑Border BNCT Oncology Cooperation

Fineline Cube Sep 8, 2026
Company Deals PIC

Guangdong Taienkang Completes Capital Increase in Procapzoom – Secures Exclusive China Rights to World‑First Ocular Surface Cell Therapy SZ018

Fineline Cube Sep 8, 2026
Company Deals PIC

HepaBio Therapeutics Raises Series A Strategic Funding From TriApex to Advance Organoid Technology and Next‑Generation Drug R&D Systems

Fineline Cube Sep 7, 2026
Company Deals PIC

Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent

Fineline Cube Sep 8, 2026
Company Drug

Hengrui Pharmaceuticals Wins NMPA Clinical Trial Approval for SHR‑1179 – First‑in‑Class Biological Candidate for Weight Management

Fineline Cube Sep 8, 2026
Company Drug

Hualan Bio Wins NMPA Clinical Trial Approval for Novel Influenza mRNA Vaccine – China’s Vaccine Major Pushes into mRNA Platform

Fineline Cube Sep 8, 2026
Company Deals

LBX Pharmacy Partners with Gilead Sciences to Enhance Disease Management in China

Fineline Cube Mar 21, 2023

China-based LBX Pharmacy has entered into a partnership with US-based Gilead Sciences, Inc (NASDAQ: GILD)....

Company Drug

Jiangsu Recbio’s ReCOV Vaccine Receives Emergency Use Authorization in Mongolia

Fineline Cube Mar 21, 2023

China-based vaccine maker Jiangsu Recbio Technology Co., Ltd (HKG: 2179) has announced that it has...

Company

WuXi AppTec Reports 71.8% Revenue Growth in 2022 Financials

Fineline Cube Mar 21, 2023

China-based WuXi AppTec Co., Ltd (SHA: 603259, HKG: 2359) released its 2022 financial report, recording...

Company Drug

Luye Pharma’s BA1102 Biosimilar to Xgeva Accepted for CDE Review

Fineline Cube Mar 21, 2023

China-based Luye Pharma Group (HKG: 2186) has announced that a market approval filing for its...

Company Drug

Bayer’s Nubeqa Receives Additional NMPA Approval for mHSPC Treatment-Fineline Info & Tech

Fineline Cube Mar 21, 2023

German pharmaceutical giant Bayer AG (ETR: BAYN) has announced that it has received another indication...

Company Drug

NMPA Denies Market Approval for Hengrui’s Plinabulin in Chemotherapy-Induced Neutropenia

Fineline Cube Mar 20, 2023

Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276) announced in a stock exchange statement that the...

Company Drug

SciClone Pharmaceuticals’ Vaborem Approved for Phase III Clinical Trial in China

Fineline Cube Mar 20, 2023

SciClone Pharmaceuticals Inc (HKG: 6600) has announced that a clinical trial filing for its Vaborem...

Company Drug

Janssen Withdraws Carvykti from UK Market Amid Manufacturing Concerns

Fineline Cube Mar 20, 2023

US-based Janssen Pharmaceutical reportedly decided to withdraw Carvykti (ciltacabtagene autoleucel; cilta-cel) from the UK market...

Company Deals

BeiGene Declines Option for Leap Therapeutics’ DKN-01 Development Rights in Asia

Fineline Cube Mar 20, 2023

US-based Leap Therapeutics Inc. (NASDAQ: LPTX) announced last week that China-based BeiGene Ltd. (HKG: 6160,...

Company Deals

Gracell Secures Non-Exclusive License for Cell Therapies from Seagen

Fineline Cube Mar 20, 2023

China-based Gracell Biotechnologies Inc. (Nasdaq: GRCL) has secured a non-exclusive worldwide license to develop and...

Company Deals

Vas Healthcare Raises RMB 100 Million in Angel Financing for Robot Development

Fineline Cube Mar 20, 2023

Vas Healthcare, a developer of vascular interventional surgery robots based in Beijing, has reportedly raised...

Company Drug

Hainan Poly Pharm’s Generic Gadovist Receives FDA Approval for MRI Use

Fineline Cube Mar 20, 2023

China-based Hainan Poly Pharm Co., Ltd (SHE: 300630) has announced that it has received marketing...

Company Drug

Jacobio Pharma’s JAB-24114 Receives CDE Approval for Phase I/IIa Clinical Study

Fineline Cube Mar 20, 2023

China-based Jacobio Pharma (HKG: 1167) has announced that it has received approval from the Center...

Company Drug

Hengrui Pharmaceuticals’ Dexmedetomidine Nasal Spray Approved by NMPA

Fineline Cube Mar 20, 2023

China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276) has announced that it has received marketing...

Company Deals

Asiflyer Bio Raises Millions in Pre-Series A Funding for Botox and ZFP Technology

Fineline Cube Mar 20, 2023

Shanghai-based recombinant protein drug developer Asiflyer Bio has reportedly raised “tens of millions” of renminbi...

Company Drug

Tot Biopharmaceutical Terminates Phase III Study for HER2-Targeted ADC TAA013

Fineline Cube Mar 20, 2023

Tot Biopharmaceutical International Co., Ltd (HKG: 1875) has announced the termination of the Phase III...

Company Drug

Shouyao Holdings Receives CDE Approval for Phase II Study of Third-Generation ALK Inhibitor

Fineline Cube Mar 20, 2023

Beijing-based Shouyao Holdings (Beijing) Co., Ltd (SHA: 688197) has announced that it has received clinical...

Company Deals

Enlight Medical Technologies to Acquire Synexmed, Expand Vascular Intervention Capabilities

Fineline Cube Mar 20, 2023

China-based Enlight Medical Technologies (Shanghai) Co., Ltd is set to fully acquire Japanese firm Japan...

Company Drug

Likang Life Sciences’ Personalized Neoantigen Vaccine LK101 Receives IND Approval

Fineline Cube Mar 20, 2023

Likang Life Sciences has announced that it has received Investigational New Drug (IND) approval from...

Company Medical Device

AffaMed Technologies’ EDOF Intraocular Lenses Receive FDA Approval in Taiwan

Fineline Cube Mar 20, 2023

AffaMed Technologies, a joint venture between AffaMed Therapeutics and SIFI S.p.A., has announced that it...

Posts pagination

1 … 600 601 602 … 717

Recent updates

  • Hengrui Pharmaceuticals Wins NMPA Clinical Trial Approval for SHR‑1179 – First‑in‑Class Biological Candidate for Weight Management
  • Hualan Bio Wins NMPA Clinical Trial Approval for Novel Influenza mRNA Vaccine – China’s Vaccine Major Pushes into mRNA Platform
  • METiS Therapeutics Partners with Hengrui Pharma – Deploying AiTEM AI Formulation Platform at China’s Leading Drugmaker
  • Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent
  • Sun-Novo Pharmaceutical and DeepMed Technology Sign Strategic Pact on AI‑Driven Drug R&D – Building Closed‑Loop “AI Design + Wet‑Lab Validation” Discovery System
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • PIC
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Hengrui Pharmaceuticals Wins NMPA Clinical Trial Approval for SHR‑1179 – First‑in‑Class Biological Candidate for Weight Management

Company Drug

Hualan Bio Wins NMPA Clinical Trial Approval for Novel Influenza mRNA Vaccine – China’s Vaccine Major Pushes into mRNA Platform

Others

METiS Therapeutics Partners with Hengrui Pharma – Deploying AiTEM AI Formulation Platform at China’s Leading Drugmaker

Company Deals PIC

Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

© 2026 Fineline Information & Technology. Independent intelligence on China's pharmaceutical industry. Not investment advice. | BlogData by Themeansar.